SGS Implements Veeva Vault Management System Globally
SGS, a life sciences, clinical, and bioanalytical contract solutions provider, announced that the company will implement the Veeva Vault CTMS (clinical trial management system) across its network of clinical operations sites for the management of its global clinical study services. Vault CTMS will enable SGS to share reporting capabilities with its clients and deliver greater flexibility in running studies. Together with Veeva Vault eTMF (electronic trial master file.) SGS will begin running studies on Vault CTMS in spring 2019, with any current studies scheduled to end after June 2019 being migrated the new system.
"Veeva Vault CTMS, along with Veeva Vault eTMF will allow us to streamline our clinical trial management and improve decision-making within our planning and operations teams across the Americas and Europe," commented Janelle Johnson, SGS International Project Mangement Director. "SGS is committed to investing where necessary to maintain its leadership position in clinical research, and ensuring it has the most efficient systems, and in-turn, offer the highest level of service and experience to our clients."
"Veeva Vault CTMS will enable SGS' to improve its operational efficiency and drive faster, higher-quality trial execution," added Henry Galio- Senior Director, Veeva Vault CTMS. Now clinicans and managers can have greater oversight and improved decision-making capabilities during studies."
SGS Life Sciences provides clinical research, bioanalytical, biologics characterization, biosafety, and quality control testing. Delivering solutions in Europe and the US, SGS offers clinical trial (phase I and IV) services encompassing clinical project management and monitoring, biometrics, PK/PD modeling and simulation, and regulatory and medical affairs consultancy. SGS has its own clinical unit in Belgium and two phase I patient units based in Belgium and Hungary. SGS has a wealth of expertise in first in human (FIH) studies, human challenge testing, manufacturing challenge agents, biosimilars, and complex PK/KD studies with a focus on infectious diseases, vaccines, and respiratory therapeutics.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
